Q-omics provides the consensus-scored TYR profile across patient tissues and cancer cell-line models. TYR expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, TYR is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, TYR RNA expression shows 9,692 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight SKCM, HNSC, and PDAC as cancer lineages where TYR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TYR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TYR survival associations across molecular data types. TYR RNA expression shows survival associations in the most cancer types (18), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TYR RNA expression–survival associations across cancer types. High TYR expression shows unfavorable associations in SKCM, UCEC, LGG and READ, but favorable associations in SCLC and HNSC. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for TYR RNA expression.
This table summarizes TYR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TYR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TYR shows lower tumor expression in HNSC and KICH and higher tumor expression in KIRP, BLCA, BRCA and THCA. The HNSC box plot shows higher TYR RNA expression in normal versus tumor tissue (log2 FC = −0.607, t-test p = .004).
This table shows molecular features associated with TYR in patient tissues and cancer cell lines. In patient samples, TYR shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, TYR RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and SKIN.
